Source: Dute
Innovation Zone Research, right at TOP Research Institute. TOP Research Institute focuses on integrated research in global innovation zones. Starting from the three dimensions of Talent (individual), Organization (organization), and Place (region), it explores the practical paths of China's innovation zone through "research/connection/sharing".
As we all know, the pharmaceutical industry is a typical "high investment, high risk, high output, long cycle" industry. Clustered development is an effective risk aversion mechanism and competitive weapon for the biopharmaceutical industry ; at the same time, new knowledge, new methods and new fields of industrial technology emerge in an endless stream. Only by learning from each other can relevant personnel ensure that knowledge is updated in a timely manner. Through physical proximity, the overall competitiveness of regional industries can be greatly improved.
FTA There are a large number of biomedical industrial cluster design practices in China, including:
Shanghai Aoyuan Oriental Beauty Valley
Nanjing Biomedical Valley
Shandong International Biomedical City
Shijiazhuang Hongtai International Biomedical City
Qingdao Lanwan Biomedical Medicine Yaogu
Handan Pharmaceutical Headquarters
etc.
At the same time, TOP Innovation Zone Research Institute has studied the world's top biological innovation clusters, and it is not difficult to find that a successful bio-innovation center will inevitably include the following roles:
First-class clinics/hospitals, universities and R&D institutions, a large number of technology-based start-ups, excellent manufacturers and backbone suppliers, as well as good venture capital funds, investment markets, etc.
: With different roles as the core, it can be divided into the following 4 modes:
Policy-oriented
For medical care, policy is a very important aspect. The government has raised the development of the medical industry to a strategic position, which means that the development of the industry provides strong support for funds, policies and intermediary services.
For example, the United States has formed a multi-level three-dimensional system at the policy level to strengthen support for the biotechnology industry. White House and Congress have both set up special biotechnology committees to track the development of biotechnology and study and formulate corresponding fiscal budgets, management regulations and tax policies.
There are also some industry organizations that have been committed to coordinating the relationship between industries and governments and promoting the government to formulate policies that are conducive to biotechnology research, development and industrial development.
This represents San Diego Shengchuang Cluster Area.
According to the EDC report, San Diego currently gathers more than 115 large gene testing companies with more than 1,100 companies in the life science field, creating an output value of about 31.8 billion US dollars each year, becoming a veritable "gene city".
Because of its remote location, it was difficult for San Diego to attract venture capital and large pharmaceutical companies at first. In order to seek development, local governments, enterprises and scientific research institutions have carried out close cooperation.
In 1996, the Industry University Cooperative Research Program (IUCRP: Industry University Cooperative Research Program) to improve the interaction between academics and industries began.
research grant has established a seed fund to promote the commercialization of scientific and technological achievements, and also allows entrepreneurs to share the experience, equipment and professional knowledge of scientific research institutions. So, the seeds of the precision medicine industry began to gradually sprout and grow in San Diego.
According to statistics, about $1.8 billion in federal funds (including the National Health Center NIH funding) and charitable budget flow into San Diego every year. In some years (such as 2014), UC San Diego is even the region in the United States that receives the most NIH funding.
In addition, San Diego also has "too many" cooperative institutions: institutions that promote regional and even international government coordination, institutions that connect universities to industry, institutions that connect industry to military, various chambers of commerce and economic development organizations, industrial boards, and even local chapters of the National Geographic Society.
is inseparable from the promotion and support of government policies.
In recent years, the country has attached great importance to the development of the biopharmaceutical industry and proposed to vigorously cultivate and develop strategic emerging industries , focus on the development of biopharmaceuticals, biomedical engineering products and other fields, and build a base for R&D and industrialization of biopharmaceuticals and biomedical engineering products, which provides basic policy support for the clustering of biopharmaceuticals. The direction of policy support for
can start from the aspects of industrial investment and talent training, encourage social funds to enter the biopharmaceutical industry, and at the same time provide high-quality talent cluster bases to expand the scale of the biopharmaceutical industry with funds and accelerate the clustering of biopharmaceuticals with talents.
Research institution-oriented
Biopharmaceutical industry is an industry based on academic research institutions as the starting point and built on academic research.
The nine major biomedical clusters in the United States are based on the agglomeration of high-level R&D institutions. For example, the Boston area gathers top scientific research institutions such as Harvard , MIT , Boston , Mass General Hospital; San Francisco is the location of Stanford and UC Berkeley ; the Washington-Baltimore-Maryland 270 Technology Corridor, known as the "Gene Capital of the World", is the location of National Institutes of Health and Johns Hopkins University.
Let's talk about Maryland 270 Technology Corridor.
According to the Maryland Department of Commerce, Maryland is the gathering place for scientists and engineers with the most doctoral degrees in the United States. In addition, it is a gathering place for governments in the United States to govern the biopharmaceutical industry, including the U.S. Food and Drug Administration (FDA), the U.S. National Institutes of Health (NIH), the USP, the Frederick National Lab for Cancer Research and Walter Reed.
NIH (National Institutes of Health), almost $14 billion is allocated annually for research grants, and the most bearer of academic funding is the famous Johns Hopkins University.
There are top academic research institutions, so there is naturally no lack of talents. There are 6,000 STEM PhDs and 10,000 professionals in the field of biohealth in the science and technology corridor, and it is no surprise to say that this is the gathering place for scientists and engineers with the most PhDs in the United States.
people are the secret weapon to attract big biopharmaceutical companies: GlaxoSmithKline (GSK), a global healthcare giant headquartered in the UK, signed a huge lease with a wave of his hand, to "compress" all the points in the United States to this "R&D headquarters" in the 270 Corridor.
Therefore, the Maryland 270 Technology Corridor "a group of new startups revolve around some famous research institutions" has moved towards a "real regional bio-pharmaceutical industry cluster innovation zone."
According to statistics, nearly 500 various industrial parks in my country include the pharmaceutical sector. However, there has been a biopharmaceutical industry cluster and less than 1/10 of which have R&D functions. The pharmaceutical industry in most parks is still in a development state of small scale, scattered enterprises, insufficient innovation, and low added value.
In the future, clusters with R&D capabilities can promote the transformation of new and old kinetic energy in regional development, and drive strong demonstration and industrial level improvement in innovative development in surrounding areas.
Company-oriented
Industrial agglomeration can improve labor productivity. British economist Marshall found that the concentrated manufacturers are more efficient than single isolated manufacturers ( external economy ). The geographical concentration of enterprises in related industries can promote the division of labor and cooperation of the industry within the region.
The Grand Est region of France is the "home" of 150 medical technology companies. More than five medical technology startups will be born every year in this small place, the size of a palm. Biomedical clusters help companies build collaborative projects, from prototypes to final products, and make it easier to raise funds and find new business opportunities.
There is an Medical Valley in Nuremberg, Germany.One of the predecessors of Siemens Medical Company was established here, and since then, the medical industry has become one of the most important industries in the surrounding area of Nuremberg . In 1895, Wilhelm Conrad Röntgen founded the first medical imaging companies in the area after Wilhelm Conrad Röntgen discovered X-ray in nearby Würzburg.
Today, there are more than 180 medical technology companies in the region with more than 16,000 employees. Many technical masters in this field, including stealth champions, such as computed tomography , magnetic resonance tomography, interventional diagnostic imaging, laser refractive surgery, lithotripsy, endoscopic treatment systems, sensors, medical information systems, and high-tech implants, are all gathered here.
At the same time, a large number of highly specialized small and medium-sized enterprises are gathered here to provide slightly larger medical technology companies with new materials in the electronic and microsystem technology, information and communication technology, optical engineering and medical equipment industries.
Usually a leading enterprise in the field of biotechnology has a scale of 5 to 10 times that of followers in the research stage and 30 to 100 times that of followers in the commercialization stage.
It is this scale effect that absorbs and equips some key resources for a regional industrial cluster.
Medical institution-oriented
It is difficult for anyone to deny that excellent hospitals are an extremely scarce and difficult to replicate. After all, the largest and most clinical data will be produced here.
Texas Medical Center (TMC for short) is a representative of this path.
Speaking of this TMC, it is the world's largest "comprehensive city" of life sciences, and is one of the cities - about 3 miles south of downtown Houston, with 106,000 employees, and receives 8 million patients each year, covering an area of 1,345 acres (8,164 acres, 5.4 square kilometers).
Here, a large amount of clinical medical data is generated every day, while pharmaceutical companies and academic researchers are able to work side by side with clinicians, while TMC's 61 institutions promote cooperation in a culture of competition within the 61 institutions. Let cooperation + competition ultimately produce results that are beneficial to all participants. The same is true for the "routines" of
Longwood Medical and Academic Area (LMA). Here, the density of medical institutions is very high and brings together top medical institutions in the United States.
Here are the top hospital resources: Beth Israel Deaconess Medical Center , Boston Children's Hospital, Danna Fabo Cancer Hospital, Brigan Women's Hospital, Israel Hospital; Danna Farber Cancer Research Center, Shapiro Cardiovascular Disease Research Center, Joselin Diabetes Center, etc.
Of course, they cooperate with Harvard Medical School , Massachusetts School of Pharmaceuticals and Health Sciences and other research institutions, and the most efficient life science ecosystem was also born here.
According to BCG statistics, there are as many as 141 biotechnical pharmaceutical companies in China from 2010 to 2020, a growth of 178% compared with 2000 to 2010. Compared with the negative growth of large economies such as the United States, Europe, and Japan in the same year, China's biotechnical pharmaceutical entrepreneurship trend is quite prosperous.
Corresponding to this, the development of biomedical parks is also in a good way. The four major paths above
are the practical experience of the world's leading medical aggregation innovation zone. In fact, no matter which path, it leads to deeper moat barriers, more interconnected industrial aggregation, and more cutting-edge industrial technology.
Edited by Liu Chunyu Reviewed by Wang Xinlin
(Author: Shenzhen Special Zone Daily reporter Xiao Xiongpeng)
This article comes from [Du Special] and only represents the author's views. National Party Media Information Public Platform provides information release and dissemination services.
ID: jrtt
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-